Clinical Trial Update: Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab for acute lymphoblastic leukemia with minimal residual disease was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Minimal Residual Disease

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Washington | Conditions: B Acute Lymphoblastic Leukemia, Minimal Residual Disease | Phase 2 | Status: TERMINATED | Results posted: 2020-08-11